NYSE$TAK
Takeda Pharmaceutical Co Ltd-ADR · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Takeda reported fiscal 2025 revenue of ¥4.58T with net profit attributable to owners of ¥317.0B and core EPS of ¥491.
For the year ended March 31, 2025, revenue rose 7.5% to ¥4.58T on growth in GI, rare disease, PDT, oncology, and vaccines, partly offset by VYVANSE generic erosion. Net profit attributable to owners was ¥317.0B; core EPS was ¥491.
- FY25 revenue ¥4.58T (+7.5% AER).
- Net profit ¥317.0B; core EPS ¥491.
- Growth brands include ENTYVIO and TAKHZYRO.
- Neuroscience pressured by U.S. generic competition.
- Pipeline investments and efficiency program ongoing.
Headline financials
Revenue & EPS history
Takeda · Revenue · Quarterly
¥4.58T
Forward guidance
Takeda discusses pipeline launches, geographic mix, and core EPS targets in annual reporting rather than quarterly U.S.-style guidance in the 20-F.
Tailwinds
- Growth in GI, rare disease, oncology, and vaccines.
- Core EPS growth and dividend policy.
- Pipeline readouts and geographic expansion.
Headwinds
- VYVANSE and mature product generic erosion.
- FX translation on yen reporting.
- R&D and integration spend on large programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-0.7%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.3%
Avg return
30 days after
39%
24 / 62 earnings
Positive
+6.3%
Q1 2019
Best reaction
-7.5%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | -1.4% | -2.1% | -5.8% | |
| Q3 2026 | +1.5% | -4.6% | +0.1% | |
| Q2 2025 | -3.9% | -1.5% | +4.7% | |
| Q1 2025 | -4.2% | -0.4% | +4.7% | |
| Q4 2024 | -5.1% | -8.9% | -0.7% | |
| Q1 2024 | +1.5% | +1.2% | +9.1% | |
| Q4 2023 | +1.5% | +3.0% | +3.1% | |
| Q3 2023 | -2.2% | -3.0% | -0.3% | |
| Q2 2023 | -7.1% | -6.2% | -3.2% | |
| Q1 2023 | -0.9% | -2.1% | -1.4% | |
| Q4 2022 | -3.5% | -3.1% | -4.5% | |
| Q3 2022 | +0.8% | +0.4% | -1.5% | |
| Q2 2022 | +1.8% | +2.4% | +12.4% | |
| Q1 2022 | -0.5% | -4.8% | -6.7% | |
| Q4 2021 | -1.8% | -1.7% | -7.8% | |
| Q3 2021 | +0.5% | +3.2% | +2.9% | |
| Q2 2021 | +1.4% | +2.8% | -2.1% | |
| Q1 2021 | -1.1% | -2.5% | -1.8% | |
| Q4 2020 | -0.7% | +0.9% | +2.4% | |
| Q3 2020 | -1.4% | +1.6% | +0.2% | |
| Q2 2020 | -4.4% | -1.6% | +11.6% | |
| Q1 2020 | +2.0% | +1.5% | +3.4% | |
| Q4 2019 | +5.5% | -0.9% | +3.8% | |
| Q3 2019 | +3.2% | +4.4% | -7.6% | |
| Q2 2019 | +3.3% | +6.6% | +12.3% | |
| Q1 2019 | +6.3% | +3.6% | +0.5% | |
| Q4 2018 | -7.5% | -10.4% | -11.0% | |
| Q2 2018 | -3.0% | -6.9% | -5.5% | |
| Q1 2018 | -1.7% | -0.3% | -1.2% | |
| Q4 2017 | -2.7% | +1.1% | -13.1% | |
| Q3 2017 | +0.4% | +2.5% | +5.3% | |
| Q2 2017 | -0.9% | -0.3% | +2.3% | |
| Q1 2017 | -0.8% | -2.2% | +3.1% | |
| Q4 2016 | -1.5% | -0.8% | +3.0% | |
| Q3 2016 | +0.1% | +2.3% | +1.3% | |
| Q2 2016 | -0.2% | -0.9% | -3.4% | |
| Q1 2016 | -1.6% | -0.6% | +4.0% | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -2.0% | — | — | |
| Q2 2015 | +1.4% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -3.7% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | -1.6% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | -6.4% | — | — | |
| Q3 2012 | +1.6% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +1.0% | — | — | |
| Q2 2011 | -0.7% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q4 2010 | -2.5% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q2 2010 | -0.2% | — | — | |
| Q1 2010 | +1.7% | — | — | |
| Q4 2009 | -0.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro